A Global Analysis of Mucormycosis in France: The RetroZygo Study (2005-2007)
Top Cited Papers
Open Access
- 13 January 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 54 (suppl 1), S35-S43
- https://doi.org/10.1093/cid/cir880
Abstract
Background. Mucormycosis is a deadly invasive fungal infection whose characteristics are only partially understood. Methods. Data on mucormycosis obtained in France between 2005 and 2007 from 2 notification systems were merged. The 2008 European Organisation for Research and Treatment of Cancer/Mycoses Study Group definition criteria were applied and risk factors for death were analyzed by hazard ratios (HRs) calculated from the Cox proportional hazards regression model. Results. A total of 101 cases (60 proven, 41 probable), mostly in men (58%) >50 years (mean age, 50.7 ± 19.9) were recorded. Hematological malignancies represented 50% (median time for occurrence, 8.8 months after disease onset), diabetes 23%, and trauma 18% of cases. Sites of infection were lungs (28%; 79% in hematology patients), rhinocerebral (25%; 64% in diabetic patients), skin (20%), and disseminated (18%). Median time between first symptoms and diagnosis was 2 weeks. The main fungal species were Rhizopus oryzae (32%) and Lichtheimia species (29%). In cases where the causative species was identified, R. oryzae was present in 85% of rhinocerebral forms compared with only 17% of nonrhinocerebral forms (P < .001). Treatment consisted of surgery in 59% and antifungals in 87% of cases (liposomal amphotericin B in 61%). Ninety-day survival was 56%; it was reduced in cases of dissemination compared with rhinocerebral (HR, 5.38 [2.0–14.1]; P < .001), pulmonary (HR, 2.2 [1.0–4.7]; P = .04), or skin localization (HR, 5.73 [1.9–17.5]; P = .002); survival was reduced in cases of hematological malignancies compared with diabetes mellitus (HR, 2.3 [1.0–5.2]; P < .05) or trauma (HR, 6.9 [1.6–28.6], P = .008) and if ≥2 underlying conditions (HR, 5.9 [1.8–19.0]; P = .004). Mucormycosis localization remained the only independent factor associated with survival. Conclusions. This 3-year study performed in one country shows the diverse clinical presentation of mucormycosis with a high prevalence of primary skin infection following trauma and a prognosis significantly influenced by localization.Keywords
This publication has 16 references indexed in Scilit:
- The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic miceJCI Insight, 2010
- The role of neutrophils in the development and outcome of zygomycosis in haematological patientsClinical Microbiology & Infection, 2009
- Forty-one recent cases of invasive zygomycosis from a global clinical registryJournal of Antimicrobial Chemotherapy, 2009
- Increasing Incidence of Zygomycosis (Mucormycosis), France, 1997–2006Emerging Infectious Diseases, 2009
- Epidemiology and Outcome of Invasive Fungal Infection in Adult Hematopoietic Stem Cell Transplant Recipients: Analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance RegistryClinical Infectious Diseases, 2009
- Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus GroupClinical Infectious Diseases, 2008
- Zygomycosis in Solid Organ Transplant Recipients in a Tertiary Transplant Center and Review of the LiteratureAmerican Journal of Transplantation, 2006
- Molecular Identification of Zygomycetes from Culture and Experimentally Infected TissuesJournal of Clinical Microbiology, 2006
- Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported CasesClinical Infectious Diseases, 2005
- Mucormycosis: Emerging Prominence of Cutaneous InfectionsClinical Infectious Diseases, 1994